CytoMed Therapeutics Limited (GDTC) AI Stock Analysis

23 Followers

CytoMed Therapeutics Limited

(NASDAQ:GDTC)

Select Model

Rating:39Underperform

Price Target:$0.83▼(-1.54% Downside)

Action:downgraded

Date:10/17/26

The score is driven primarily by very weak profitability and substantial cash burn, with additional pressure from negative valuation metrics and bearish positioning below key moving averages. Low leverage and neutral short-term momentum provide limited support.

Positive Factors

Revenue GrowthThe sharp increase in TTM revenue indicates meaningful commercial expansion and growing activity in the business. If the company can retain this trajectory while controlling costs, a larger revenue base could eventually support operating leverage and improve the economics of its development programs.

Negative Factors

Persistent Cash BurnPersistent negative operating and free cash flow means the business is consuming cash rather than funding itself internally. Unless burn moderates, continued reliance on external capital may constrain strategic flexibility, increase financing requirements, and make pipeline investment harder to sustain.

CytoMed Therapeutics Limited (GDTC) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $9.99M
Dividend Yield: ―
Average Volume (3M): 17.55K
Price to Earnings (P/E): -2.4
Beta (1Y): 0.05
Revenue Growth: 49.09%
EPS Growth: 3.91%
Country: US
Employees: 42
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CytoMed Therapeutics Limited Business Overview & Revenue Model

Company Description

CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancie...

How the Company Makes Money

null

CytoMed Therapeutics Limited Financial Statement Overview

Summary

Financial performance is very weak: substantial operating and net losses, deeply negative margins, negative operating cash flow of $5.58 million, and negative free cash flow of $6.30 million. Low debt relative to equity is the primary offset.

Income Statement

12Very Negative

Balance Sheet

58Neutral

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	720.31K	324.39K	69.50K	0	0	0
Gross Profit	-4.16M	256.39K	52.38K	-4.36M	0	110.29K
EBITDA	-4.84M	-3.57M	-2.17M	-3.70M	-2.61M	-1.56M
Net Income	-5.26M	-3.98M	-2.52M	-4.13M	-3.13M	-2.07M
Balance Sheet
Total Assets	7.01M	7.98M	10.07M	12.40M	5.25M	6.10M
Cash, Cash Equivalents and Short-Term Investments	1.46M	2.10M	4.97M	9.02M	1.59M	2.53M
Total Debt	453.76K	482.56K	463.15K	449.25K	4.24M	3.27M
Total Liabilities	1.61M	1.13M	1.02M	1.13M	4.66M	3.50M
Stockholders Equity	4.97M	6.54M	8.96M	11.28M	589.71K	2.60M
Cash Flow
Free Cash Flow	-6.30M	-4.40M	-4.11M	-3.60M	-1.88M	-2.30M
Operating Cash Flow	-5.58M	-3.70M	-2.71M	-3.54M	-1.40M	-1.72M
Investing Cash Flow	1.70M	929.28K	1.13M	-2.73M	-475.51K	-825.59K
Financing Cash Flow	1.53M	208.65K	-64.88K	10.92M	968.35K	4.18M

CytoMed Therapeutics Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price0.84

Price Trends

50DMA0.89Negative

100DMA0.91Negative

200DMA0.98Negative

Market Momentum

MACD-0.01Positive

RSI41.91Neutral

STOCH35.24Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Negative. The current price of 0.84 is below the 20-day moving average (MA) of 0.89, below the 50-day MA of 0.89, and below the 200-day MA of 0.98, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 41.91 is Neutral, neither overbought nor oversold. The STOCH value of 35.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDTC.

CytoMed Therapeutics Limited Risk Analysis

CytoMed Therapeutics Limited disclosed 106 risk factors in its most recent earnings report. CytoMed Therapeutics Limited reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

CytoMed Therapeutics Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GDTC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MTVA	53Neutral	$9.49M	-0.32	-209.67%	―	―	79.26%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PASG	48Neutral	$12.87M	-0.40	-377.94%	―	―	28.49%
AKTX	43Neutral	$13.04M	-0.00	-147.45%	―	―	―
GDTC	39Underperform	$9.94M	-2.38	-91.37%	―	49.09%	3.91%

* Healthcare Sector Average

Performance Comparison

GDTC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GDTC	CytoMed Therapeutics Limited	0.84	-1.12	-56.94%
AKTX	Akari Therapeutics PLC (ADR)	6.51	-14.64	-69.22%
MTVA	Metavia Inc.	1.30	-6.39	-83.09%
PASG	Passage Bio, Inc.	4.01	-4.84	-54.69%
KAPA	Kairos Pharma, Ltd.	0.48	-5.32	-91.73%

CytoMed Therapeutics Limited Corporate Events

CytoMed Therapeutics Posts Narrower Interim Loss in June 2026 SEC Filing

Sep 30, 2026

CytoMed Therapeutics Limited has filed a Form 6-K with the U.S. Securities and Exchange Commission for the financial period ended June 30, 2026, furnishing unaudited interim condensed consolidated financial statements and management’s discussion and...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 17, 2026

CytoMed Therapeutics Limited AI Stock Analysis